Unique ID issued by UMIN | UMIN000010656 |
---|---|
Receipt number | R000012466 |
Scientific Title | Relationship between alcohol metabolism and chemotherapy induced emetic events |
Date of disclosure of the study information | 2013/05/07 |
Last modified on | 2014/12/10 09:18:56 |
Relationship between alcohol metabolism and chemotherapy induced emetic events
Relationship between alcohol metabolism and chemotherapy induced emetic events(ACHIEVE study)
Relationship between alcohol metabolism and chemotherapy induced emetic events
Relationship between alcohol metabolism and chemotherapy induced emetic events(ACHIEVE study)
Japan |
Breast cancer
Breast surgery | Adult |
Malignancy
YES
The correlation between habitual alcohol consumption and CINV has been reported but it would be worthwhile to ascertain the underlying mechanism, specifically whether Japanese subjects, 40% of whom lack one of the alleles of ALDH2 gene which is related to the alcohol-metabolizing enzyme, are particularly supposed to be susceptible to CINV. To elucidate the mechanism of CINV, as our primary endpoint, we examined whether genetic polymorphism of ALDH2 and habitual alcohol consumption are related to CR. As the secondary endpoint, we investigated the relationships between CC( complete control) and CRs, which are divided into the early, delayed and all phases, and those between ALDH2 genetic polymorphisms and habitual alcohol consumption in women with breast cancer who received an AC therapy.
Efficacy
Exploratory
We investigate the relationship between CR (complete response) and genetic polymorphism of ALDH2 to elucidate the mechanism of CINV whether ALDH2 and habitual alcohol consumption are related to CR.
We investigate the relationships between CC( complete control) and CRs, which are divided into the early, delayed and all phases, and those between ALDH2 genetic polymorphisms and habitual alcohol consumption in women with breast cancer who received an AC therapy.
Observational
20 | years-old | <= |
55 | years-old | > |
Female
The subjects were breast cancer patients treated with first course of FEC (Fluorouracil (5-FU), epirubicin and cyclophosphamide )as one of AC therapies, at the outpatient clinic of our hospital between 2012 and 2014 and who met the following criteria: 20 to 55 years of age, female, disease at stages I-III and a performance status (PS) of 0-1.
Patients who are judged to be inappropriate for the study by the investigator.
81
1st name | |
Middle name | |
Last name | Mitsue Saito |
Juntendo University Hospital
Department of Breast Oncology
3-1-3, Hongo, Bunkyo-ku, Tokyo 113-8421
03-3813-3111
mitsue@juntendo.ac.jp
1st name | |
Middle name | |
Last name | Toshitaka Uomori |
Juntendo University Hospital
Department of Breast Oncology
3-1-3, Hongo, Bunkyo-ku, Tokyo 113-8421
03-3813-3111
tuomori@juntendo.ac.jp
Juntendo Clinical Research Support Center
Department of Breast Oncology,Juntendo University Hospital
Self funding
NO
順天堂大学医学部附属順天堂医院(東京)
2013 | Year | 05 | Month | 07 | Day |
Unpublished
No longer recruiting
2012 | Year | 12 | Month | 28 | Day |
2013 | Year | 05 | Month | 07 | Day |
2014 | Year | 09 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
ALDH2 gene is investigated using 0.5ml of residual blood from regular check-up blood testing sample of each breast cancer patient.
2013 | Year | 05 | Month | 07 | Day |
2014 | Year | 12 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012466